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ABSTRACT 
Aims/Introduction: Peptides are considered as quasi-hormones and effective molecules for 
regulation of the cells function and metabolic disorders prevention. Di- and tripeptides with 
the ability to gastrointestinal absorption have been proposed to prevent diabetes progression. 
 
Materials and Methods: Small peptides with different sequences of specific amino acids 
were synthesized based on a solid phase peptide synthesis (SPPS) protocol as well as 
carnosine (A) and glutathione (B) were examined for the prevention of diabetes induced by 
multiple low-dose of streptozotocin (MLDS) in mice.  
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Results: The peptides A, Leu-Gly (D) and Pro-Pro (F) exhibited a preventive effects on 
blood glucose elevation and impairment of the signaling and performance of beta cells. The 
beta cells function assessed by immunofluorescence and blood glucose level in mice exposed 
to diabetes treated by the peptides A and D was similar to the normal mice. The peptide D 
prevented from body weight loss caused by diabetes induction. The use of D and A peptides 
dramatically prevents the incidence of disruption in beta cells signaling by maintaining the 
natural balance of intracellular Akt-2 and cAMP. 
 
Conclusions: The results proved that peptide D (Leu-Gly) named Hannaneh inhibits the body 
weight loss caused by diabetes induction. The Hannaneh and carnosine dipeptides with 
preservation of normal beta cell signalling and anti DPP-4 activity were prevented from 
increasing the blood glucose in mice at risk of diabetes. These dipeptides may be regarded as 
the pharmaceutical agents for the prevention of diabetes. 
Keywords: Beta cell, Glucose,  peptide, 
 
INTRODUCTION 
Recent years have witnessed a peptides revolution as a result of newly discovered influences 
of peptides on different physiological systems. Small peptides are defined as quasi-hormones 
and pharmaceutical agents; these bioactive molecules can modulate the cells physiological 
functions1. Bioactive small peptides can be absorbed from the intestine directly into 
bloodstream via the PepT1 H+/peptide co-transporter2. After enteric absorption, the pancreas 
is one of the important organs as it is exposed to high concentrations of absorbed bioactive 
peptides. Beta cells in the pancreas are one of the major cellular targets for bioactive 
peptides3, 4. 
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Beta cells are very sensitive to apoptotic damage induced by oxidative and inflammatory 
induced compounds. Streptozotocin (STZ) as a chemical toxin binds to the GLU2 receptors 
on beta cells5, 6. Administration of multiple low-dose streptozotocin (MLDS) induces 
distortion of the beta cells in conjunction with mononuclear cell infiltration and apoptosis by 
caspases enzymes, DNA mutilation, nitric oxide production, and free radical generation7, 8. It 
is known that the STZ model of diabetes simulates the complications of human diabetes. 
Given the established similarities of some structural, functional, and biochemical 
abnormalities to human disease, it is an appropriate model for assessing the mechanism of 
diabetes7. Although there is disagreement among researchers, the majority agree that MLDS 
generated mild hyperglycemia (200 - 400 mg/dl) in experimental mice gives insulin secretion 
that is similar to human T2D9. However, there are conflicting reports indicating that 
administration of MLDS in first days generates T2D and in progression produces T1D10, 11. 
GLP-1, a major incretin hormone released in response to nutrient intake and bloodstream 
amino acids and peptides, contributes over 50% of postprandial glucose-stimulated insulin 
release and plays important roles in insulin secretion and maintaining normal glucose 
regulation12, 13. The durability of this hormone is transient because it is rapidly cleared by the 
kidney and inactivated by cleavage at the N-terminal by dipeptidyl peptidase-4 (DPP-4) 
enzyme14. Therefore, it is important for T2D therapy to develop a potent DPP-4 inhibitor, 
GLP-1 stimulator, and direct beta cell-signaling activator from natural sources such as 
peptides15. The receptors for GLP-1 are located in the pancreas of humans and mice. Previous 
studies have demonstrated the proliferative and antiapoptotic effects of GLP-1, leading to the 
expansion of the mass of beta cells and improved glucose homeostasis in T2D14, 16. The 
serine/threonine-specific protein kinase Akt-2, also known as protein kinase B (PKB), 
intracellular enzyme for beta cells, plays an important role in signal transduction downstream 
of the insulin receptors. Activation of Akt-2 signaling in mice constitutively overexpressing 
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activated Akt-2 and cyclic AMP (cAMP) as the second messenger for regulation of insulin 
exocytosis in beta-cells resulted in increased islet mass, largely owing to neogenesis, 
proliferation of beta cells, and improved glucose tolerance. Therefore, Akt-2 might represent 
a potential target to improve beta cell proliferation and survival18, 19. GLP-1 may activate 
Akt-2 signaling of the cAMP-dependent pathways in beta cells. cAMP signaling is one main 
factor in transducing GLP-1mediated activities in beta cells. On the other hand, GLP-1 has 
been shown to improve both beta cell proliferation and survival via cAMP-dependent 
stimulation of the cAMP in mice18, 19. 
One of the main causes of diabetes development is linked to oxidation phenomenon. 
Therefore, antioxidative peptides may exert antidiabetic effects, particularly in the 
prediabetes stage20, 21. Some histidine (His)-containing peptides, particularly the dipeptide 
known such as carnosine (β-alanine-L-histidine), exhibit antioxidant activity20, 22. The 
tripeptide glutathione exists in natural tissues and is important in the regulation of the redox 
state and protection of cells from oxidative damage by the disposal of free radicals, which 
have a pathogenic effect in the chronic complications of diabetes23. Hydrophobic amino acids 
such as proline (Pro) and leucine (Leu), especially in the C- and N-terminals of peptides, 
have antioxidative effects20. Pro is an essential amino acid in regulating gene expression, cell 
signaling, and antioxidative responses. This amino acid also modulates protein–protein 
interactions, thus playing important roles in many cell-signaling pathways. Leu is an 
important branched-chain amino acid owing to its most popular benefit in the metabolism. It 
activates the mTOR and cAMP pathways, leading to increased protein synthesis, specifically 
insulin, by beta cells (as an insulin production stimulator) and prevents mitochondrial gene 
mutations (one of the causes of diabetes and obesity). Leu and its small peptides are known to 
stimulate insulin secretion from pancreatic beta cells by serving as metabolic fuel and 
regulating cell metabolism. Furthermore, Leu peptides regulate the expression of key 
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metabolic genes in beta cells as a new opportunity for prevention of islet dysfunction and 
diabetes23, 24. The peptides of the glyproline family exhibit various bioactivities and the linear 
glyproline peptides are relatively stable (t1⁄2 of Pro-Gly-Pro is more than 24 h)
 24-26, 28. 
The objective of the present study was to investigate the antidiabetic effects of di- and tri-
peptides with different sequences consisting of three specific amino acids, including Pro, Gly, 
and Leu. 
 
MATERIALS AND METHODS  
Peptides synthesis 
Experimental peptides were synthesized using a classical glass reaction vessel following the 
Fmoc solid-phase peptide synthesis protocol29, 31. The 2-CTC resin (specific for Pro and Gly 
peptides to prevent diketopiperazine formation) was swelled in dry DMF (this resin is 
extremely moisture-sensitive) for 1 h. Then the DMF was filtered under vacuum. The first 
amino acid at the C-terminal of the peptide was coupled in the presence of TBTU and DIPEA 
in dry DMF by mixing with nitrogen gas for 2 h. After the completion of the coupling 
reaction (which was confirmed by Kaiser test30 for Leu and Gly and isatin test for Pro29), the 
solution was filtered off and then the resin coupled with the first amino acid was washed with 
DMF (3×2 mL) and DCM (3×2 mL). In order to ensure that no unreacted sites remained on 
the resin, the resin was end-capped (twice) using HPLC-grade methanol MeOH. The N-
terminal Fmoc deprotection was performed using piperidine in DMF (20% v/v, 10 mL, and 
2×30 min). The resin was washed with DMF (3×2 mL) and DCM (3×2 mL). The 
subsequently activated amino acids were coupled in a similar manner. The resin was washed 
(three times) with DMF and DCM, sequentially, at the end of all stages. After obtaining the 
required peptide sequence, the resin–peptide was dried under vacuum for 24 h. Fresh 
cleavage cocktail, composed of 5% TFA in DCM, was added to the resin–peptide. The 
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mixture was shaken at room temperature for 2 h then the resin was collected by filtration. The 
isolated peptide was washed with another 2 mL of cleavage cocktail. The combined filtrates 
containing 5% TFA in DCM and the peptides were evaporated to a minimum volume using a 
nitrogen evaporator. The resulting solution was lyophilized for 24 h. Purification of peptides 
was carried by analytical RP-HPLC using a Zorbax 300 SB-C8 narrow bore column with a 
linear AB gradient (1% acetonitrile/min) at a flowrate of 0.25 mL/min, where eluent A was 
0.2% aq. TFA, pH 2, and eluent B was 0.2% TFA in acetonitrile. Eventually, about 200 mg 
of each di- and tri-peptide was obtained. The chemical structures of the seven most effective 
peptides that were produced and studied in the present research are shown in Figure 1. 
 
Animals, experimental design and tested peptides 
Male BALB/c mice (age 9-10 weeks) were purchased from the Pasteur Institute of Tehran 
(Iran) and were housed in a controlled environment in a specific pathogen-free animal facility 
at 22°C under a 12: 12 h light: dark cycle at the Drug Applied Research Center, Tabriz 
University of Medical Sciences. The normal diet and water were offered ad libitum. 
Following animal adaptation to the environment for 1 week, all mice were weighed, labelled, 
and allocated to treatment groups on the basis of the average weight (35.4±0.3 g) (10 male 
mice per group). After a week of re-adaptation, the experiment was started. On the first day 
of the experiment, simultaneous injection of STZ and peptides was commenced. Diabetes 
was induced by MLDS injection on the left side of the intraperitoneal (IP) space. For this 
purpose, The STZ (S0130/Sigma) was dissolved in 0.1 M citrate buffer (pH 4.5) and injected 
within 20 min of preparation at a dose of 50 mg/kg/day for 5 consecutive days. Coinciding 
with the STZ injection, each of the peptides was injected on the right side every day (peptides 
dissolved in dimethyl sulfoxide, DMSO, 3% in PBS and injected at 20 mg/kg of body 
weight/day). Briefly, the experimental treatments were as follows: in the control group 
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(CON), mice received bilateral IP injections of citrate buffer without STZ (left side) and PBS 
without peptide (right side). In the group exposed to diabetes (DI), the mice received bilateral 
IP injections of STZ (left side) and PBS without peptide (right side). The third group (DM) 
was mice exposed to diabetes and 3% DMSO that received bilateral IP injections of STZ (left 
side) and PBS + 3% DMSO without peptide (right side). The other groups of mice received 
peptides and exposed to diabetes where each group received one of the peptides dissolved in 
3% DMSO in the PBS, the mice with bilateral IP injections of STZ (left side) and one of the 
peptides + 3% DMSO in PBS (right side) (seven groups for the seven reported peptides from 
A to G). In all groups, STZ was injected from 1 to 5 days and peptides were injected from 1 
to 12 days continuously. The body weight of each of the labelled mice was recorded at three 
time points (1st, 6th, and 12th days of the experiment).  
In this study, 15 peptides including Leu-Pro-Pro, Leu-Pro, Leu-Leu, Leu-Leu-Gly, Leu-Gly, 
Leu-Leu-Leu; Pro-Gly-Pro, Pro-Pro, Pro-Leu-Gly, Pro-Gly, Pro-Pro-Pro; Gly-Gly, Gly-Gly-
Gly, Gly-Pro-Gly and Gly-Leu-Gly were prepared. These peptides were tested in 3 stages 
under the same environmental and nutritional conditions, and the same mice species. In each 
of the 3 experiments there were three control groups (CON, DI and DM) and some of these 
15 peptides were tested with limited number of animals. Based on our preliminary screening 
experiments in the final stage (main experiment), a re-test with 5 peptides including Leu-Pro-
Pro, Leu-Gly, Pro-Gly-Pro, Pro-Pro, and Pro-Gly which exhibited promising anti-diabetic 
effects along with the previously known effective peptides i.e. Glu-Cys-Gly (glutathione) and 
Ala-His (carnosine) were tested. 
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Glucometry, insulin, GLP-1, and DPP-4 Assay 
On the even days of the experiment (days 2, 4, 6, 8, 10, and 12), blood samples were obtained 
from the tail vein of each mouse in the fed state and glucose was measured using a 
glucometer (GALA, TD-4277, 2016 approved by the FDA) between 9:00 and 11:00 am. 
Mice were considered diabetic when their fed blood glucose level was >200 mg/dl. 
Furthermore, the other blood samples (fed state) were taken from the orbital sinus at days 6 
(9:00 am) and 12 (11:00 am) for measurement of insulin, GLP-1, and DPP-4 at a maximum 
of 30 min after peptide injection. For this purpose, obtained sera were measured by ELISA 
kits according to the manufacturer’s instructions (AWAKNESS Technology Inc., USA), 
including an ELISA microplate reader (Stat Fax 2100) and an automatic ELISA plate washer 
(Stat Fax 2006) for mouse insulin (Sigma-Aldrich, USA), mouse GLP-1 (Eastbiopharm Inc., 
China), and mouse DPP-1 (Eastbiopharm Inc., China). 
 
Dissection and isolation of mice pancreatic islets 
At the end of the experiment, the pancreases were dissected from anesthetized (by ketamine 
and xylazine) mice. Islets were isolated from the pancreas based on the described protocol for 
collagenase digestion33. After being washed in Krebs–Ringer bicarbonate buffer solution with 
0.2% BSA, the islets were digested with 0.025% trypsin (Life Technologies) for 5 min at 
37°C and passed through a 400-mm wire mesh. The cells were then plated on coverslips that 
were coated with poly-L-lysine and maintained at 37°C in a 5% CO2 incubator for 24 h
32, 33. 
 
Immunofluorescence imaging 
The dissociated islet cells were fixed in 7% paraformaldehyde for 15 min and washed with 
0.1 M PBS with 0.3% Triton X-100 for 30 min at 37°C. After incubation in 5% BSA and 
0.15% Triton X-100 blocking solution for 1 h, the cells were incubated by primary antibodies 
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for 1 h at 4°C, washed with PBS, and incubated again with the appropriate fluorochrome-
conjugated antibodies for 1 h. Antibodies included a guinea pig anti-insulin antibody 
(Abcam, UK), a mouse anti-glucagon antibody (Abcam, UK), and a mouse anti-somatostatin 
antibody (Abcam, UK). After being thoroughly washed with PBS, immunofluorescence 
images of the islets were obtained based on minimal background under a total internal 
reflection fluorescence microscope because high background fluorescence may occur as a 
result of exocrine contamination33. 
 
Akt-2 and cAMP assay 
Isolated islets was used to assay Akt-2 and cAMP of beta cells. The extracted biomass were 
diluted in 10×volume of 0.1 M HCl, homogenized, and centrifuged at 10000 rpm for 5 min. 
After incubation, the surface liquid used for cAMP lysates was measured using the direct 
Cyclic AMP EIA kit (Assay Designs) and then Akt2 (AKT2 ELISA Kit, My Biosource, Inc. 
California, USA) according to the manufacturer’s instructions33, 45. 
 
Statistical analyses 
All variables were checked for normality using the Kolmogorov-Smirnov (K-S) test using 
SPSS, version 19.0 (SPSS Inc., Chicago, IL, USA). K-S rest revealed that all variables were 
normally distributed. Data were analyzed by one-way (glucose data) or two-way (hormone 
data) GLM procedure ANOVA using SAS for Windows release 9.2 (SAS Institute Inc., Cary, 
NC, USA). Data are reported as the mean and standard deviation (SD). The differences 
between means were studied by Duncan’s multiple-range test where P<0.05 were reported as 
statistically significant. 
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RESULTS 
Table 1 presents the mean plasma glucose levels for the six timepoints of the experimental 
period and statistically compares these values between treatments. The glucometry of the 
second day of intervention demonstrates that in the exposed to diabetes mice (DI), the 
glucose level was significantly elevated compared to the control (CON) group (111.6 versus 
94.6 mg/dl) (P<0.01). The mice received peptide E exhibited smaller amounts of blood 
glucose level than those DI and CON groups (P<0.01). On the fourth day of the trial, the 
blood glucose level was higher than that of most groups in mice that were in DM and peptide 
D groups (P<0.05). Moreover, the glucose level in the mice that received peptide E was lower 
than all other groups (P<0.05). The mice received peptides A, B, C, and G exhibited lower 
amounts of blood glucose level compared to the DI group at the 6th day. In addition to Table 
1, the charts in Figure 2 illustrate the effects of the peptides at days 10 and 12 days of the 
experiment. Ten days after the start of the trial and five days after MLDS protocol 
completion, the blood glucose was significantly higher in mice of the DI and DM groups 
compared to the CON group (174.8 and 177.3 versus 111.7 mg/dl) (Figure 2, chart L). Two 
diabetes-exposed groups treated by peptides A and D had blood glucose levels similar to 
those of the CON group (116.4 and 112.0 versus 111.7 mg/dl). The mice received other 
peptides exhibited intermediate amounts of blood glucose level between the CON and DI 
groups. In other words, peptides A and D prevented hyperglycemia under the influence of 
STZ injection at this stage (Figure 2, chart L). On the 12th day of the experiment, the mice of 
DI and DM groups were completely diabetic (glucose levels 279.3 and 219.1 mg/dl, 
respectively). Also, the results (Table 1 and Figure 2, chart R) showed that the difference 
between blood glucose levels between the DI and DM groups was significant at the end of the 
experiment (P<0.01). The mice received DMSO exhibited smaller amounts of blood glucose 
than DI group. The blood glucose levels of mice that received peptides A, D, E, and F were 
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statistically similar to those of the CON mice at the end of the experiment. It is clear that the 
differences between the glucose levels for the CON mice in the six time stages of glucometry 
were not significant (respectively, 94.6, 107.4, 120.3, 99.2, 111.7 and 118.7 mg/dl). The 
blood glucose levels in the DI mice increased with a steep slope during the six stages. Similar 
result was obtained for the DM group that received 3% DMSO in PBS, So that, the mice in 
this group (DM) were diabetic by the 12th day of the trial (219.1 mg/dl). The differences 
between the means of blood glucose levels at the six glucometry times were not significant in 
mice received peptides A, D, and F (P>0.05). This means that the use of any of these three 
peptides dramatically reduced the incidence of diabetes. However, the other peptides also 
effectively prevented the excessive increase of glucose levels until the 10th day of the trial. 
The results showed that the blood glucose levels in mice that received any of the peptides did 
not exceed 200 mg/dl (diabetic level), even on the last day. 
The body weight of the mice was determined at three time points (days 1, 6, and 12) and the 
results are shown in Figure 3. Owing to the initial control of the mice weight at the start of 
the experiment, the weight differences were not significant at the first day. On the 6th day of 
the experiment the differences in their mean body weight between treatments were significant 
(P<0.05). The induction of diabetes caused a reduction in the body weight in the DI mice, 
whereas in the CON group the body weight was significantly elevated in ascending order 
from days 1 to days 12 (Figure 3). The injection of all peptides and also DMSO prevented the 
body weight loss, except peptides A, B, and G. Peptide D was the most efficient at preventing 
body weight loss. 
As shown in Figure 4, on the 6th day of the experiment the blood insulin levels in the CON 
and DI groups were not statistically significant (5 and 5.1 mIU/L). While, the insulin level in 
the mice that received peptides E and G (3.7 and 3.0 mIU/L, respectively) especially peptides 
A and B (2.04 and 2.80 mIU/L, respectively) exhibited lower levels. Data obtained on the 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
12th day for insulin level showed that, in contrast to the 6th day, the insulin levels of the 
CON, DI, and DM mice were lower (2.9, 2.8, and 2.5 mIU/L, respectively) than insulin levels 
in mice treated by peptides A, B, and D (P<0.05). It should be noted that as mice are 
nocturnal animals and eat overnight, the level of insulin in their blood is therefore higher in 
the early morning compared to later in the morning. This could be why there was an observed 
difference in insulin level for the control group for the 6th and 12th days of the experiment. 
According to Table 2, the difference between the mean GLP-1 levels in the CON and DI 
mice was significant on the 6th day (P<0.05). The GLP-1 level was elevated in the DI group 
compared to the CON group one day after the end of the MLDS protocol. All peptides except 
peptides B and G prevented GLP-1 increasing in DI mice at the 6th day. However, the 
difference in the GLP-1 levels in the CON and DI groups was not significant on the 12th day. 
Moreover, the mice received peptides D or F and the DM group mice exhibited a decline in 
GLP-1 amounts that is not significantly different compared to the CON and DI groups. 
Development of diabetes did not have an effect on DPP-4 activity. In other words, there was 
no significant difference between CON and DI groups at 6th and 12th days of the experiment. 
Although, the use of peptides, specifically A, D, and F, caused a reduction in DPP-4 activity 
on the 6th day of the experiment (Table 2).  
Figure 5 shows that Akt-2 and cAMP levels of the isolated islets, as beta cell-signaling 
indicators, are affected (P<0.05) by treatments. The induction of diabetes (DI) has been 
associated with a sharp decline in both indicators of the intracellular signaling of beta cells 
compared to control group. Using DMSO (DM) had no effect on disorder improvement cell 
signaling. The mice received peptides B and E did not exhibited any effect on Akt-2 activity 
of the beta cells. The other peptides, particularly peptides A and D, which had a significant 
effect on Akt-2 and prevented intracellular signaling impairment of beta cells in the mice 
exposed to diabetes. The injection of the peptides C, E, and G did not have any effect on 
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cAMP levels. The mice received peptides A and D had a higher concentration of intracellular 
cAMP in their beta cells (P<0.01). While, mice treated with peptides B and F were affected to 
a certain extent. Therefore, peptides A and D prevented any interference in cell signaling by 
STZ-induced diabetes in mice. The immunofluorescence staining of the islets at the end of 
the experiment displayed a normal islet architecture, with insulin-producing beta cells in 
green and glucagon-producing alpha cells in red for the CON group (Figure 6). The severe 
destruction of endocrine cells with minimal hormonal content was observed in the islets of 
mice exposed to diabetes (Figure 6), similar cell-signaling disorder (Figure 5), body weight 
loss (Figure 3), and glucose concentration elevation (Figure 2), but not similar blood insulin 
levels. The A and D peptides showed preventing effects against the incidence of diabetes. 
The blood glucose levels were similar in mice treated with peptides A and D on the 10th and 
12th days. A significant (P<0.05) anti-DPP-4 effect was observed on the 6th day mainly for 
the mice groups receiving peptides F, D, and A. As shown in Table 2, unlike the CON and DI 
groups, the DPP-4 enzyme activity was elevated from days 6 to 12 in all peptide groups, and 
particularly in the F peptide group (P<0.05). The injection of all the reported peptides had a 
significant effects on the survival and secretion activity of the endocrine cells of the islets, 
especially the beta cells. Of course, the role of the two peptides A and D was distinct than the 
others, which reaffirmed the role of these dipeptides for maintaining the normal survival and 
hormonal secretion of beta cells in mice exposed to STZ-induced diabetes. 
 
DISCUSSION 
Recent sdnidnif have indicated the roles of small peptides as drug active agents that can 
modulate the physiological functions for the prevention of diabetes13, 44. The present study 
reports the preventive effects of small peptides in mice exposed to diabetes by hormonal 
(insulin and GLP-1) and enzymatic (DPP-4) communications involved in glucose 
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homeostasis. Small peptides with insulinotropic and GLP-1 tropic effects combat obesity and 
T2D26. In vitro and in vivo studies highlighted the potential of the peptides referred to in the 
BIOPEP database for functioning antidiabetic effects and recommended more in vivo studies 
for assessment of the type and sequences of these small active peptides37. In addition, the 
moderate effect of DMSO as an organic solvent on diabetes suppression has already been 
confirmed in previous studies36.  
In the present study, it has been demonstrated that the produced peptides from proline, 
glycine and leucine especially Leu-Gly and carnosine (Ala- His) dipeptides caused a 
significant prevention of blood glucose elevation in mice at risk of diabetes. It has recently 
been reported that the tripeptides of glycine-glycine-leucine (Diapin) elevated the plasma 
insulin and GLP-1 levels in diabetic mice30. In the present study, the peptides A and D 
prevented the increase of GLP-1. The results showed that the peptides A and D have anti-
DPP-4 effect as diabetes incidence mechanism of MLDS as described by Lin et al. 2010, and 
blood glucose elevation 7 days after the beginning of the experiment8. Dietary amino acids 
and peptides can also induce insulin secretion via GLP-1 stimulation mechanisms. Also, 
some cell-permeable peptides as inhibitors of the c-Jun NH2-terminal kinase prevent 
cytokine-induced β-cell apoptosis. A wide range of short-length peptides have been reported 
to possess DPP-4 inhibitory activity and effective at stimulating insulin secretion and 
improving glycemic control in animal models and subjects with T2D33, 38.  
The results of insulin measured on the 12th day indicated that the elevated glucose levels of 
the diabetes exposed group has no relationship with insulin level. The elevation of blood 
glucose level promotes an increase demand on the pancreatic beta cells to secrete insulin to 
bring the glucose content in the blood to a normal level. Since this homeostasis mechanism 
reduces blood glucose during the prediabetes stage of diabetes development, chronic and 
persistent insulin resistance exposes the beta cells to an excess of glucose, thereby promoting 
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beta cell dysfunction, failure, and death. The beta cells respond to many nutrients in the blood 
circulation, including glucose, other monosaccharaides, amino acids, and peptides19, 33. The 
peptides A and D significantly caused insulin elevation compared to both control and 
diabetes induced groups without increasing GLP-1 and the depression of DPP-4 on the 12th 
day. Therefore, the therapeutic agents that can halt or prevent pancreatic β-cell failure will 
likely have a major impact on disease progression. The action mechanism of small peptides 
in target cells is conditioned by their binding to special membrane receptors and are able to 
influence physiological functions44. The peptide substances have shown direct regulators or 
mediators of physiological processes38. The important factor for a peptide action is the 
stability of the peptide in the bloodstream. The glyproline family were most stable in blood38 
and the peptides containing branched chain amino acids mainly, leucine, induced an increase 
in GLP-139. The endogenous peptides of containing leucine stimulated insulin secretion in 
vitro and in vivo40. In a study involving several animal models of insulin resistance, leucine 
containing peptides displayed antidiabetic effects with a suppression in the elevation of blood 
glucose. It should be noted that all blood samplings and STZ administration in the present 
study were in fed state. MLDS under fed or fasted conditions is equally effective in 
experimental hyperglycemia and fasting state prior to administration of MLDS is not 
required. Also, fasting may be an unnecessary step in the experimental design and it is an 
unnecessary metabolic stress to the mice under the study40.  
A significant increase in the body weight in the control group was observed in the present 
experiment (Figure 3) whereas, a marked depression in the body weight was observed in 
diabetes exposed group. Takeda et al. (2012) reported that body weight increased throughout 
the study in non-diabetic control mice, whereas mice injected with STZ lost their body 
weight irrespective of the treatment42.  
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The cellular nutrition and stimulation of beta cell mitosis by these peptides can be a major 
factor in the prevention of the effects of STZ induced diabetes. In the present study, most of 
the synthesized peptides especially Leu-Gly completely prevented the body weight loss under 
the influence of diabetes development. Also, only dipeptide Leu-Gly had the greatest 
protection on both glucose elevation and body weight loss. The authors have named this 
peptide “Hannaneh” which means it is reliable. The presented results showed that hannaneh 
and carnosine can effectively prevent the rise of blood glucose elevation in the onset of 
diabetes. The hannaneh peptide has mild anti-DPP-4 and stimulates the insulin secretion 
effects probably based on the immunofluorescence imaging. 
Previous studies have shown that dipeptides have multiple physiological functions, including 
anti-inflammation, anti-oxidant and anti-diabetic effects or increased diabetic wound 
healing43. Furthermore, it can be postulated that these dipeptides activate AMP-protection 
kinase (AMPK). AMPK has been identified as an important target in the prevention and 
treatment of obesity and T2D43. It was reported that the synthetic di- and tripeptides 
containing glycine such as glycine-leucine (reverse in N and C-terminal of amino acid in 
compare with peptide hannaneh) are a strong stimulus for GLP-1 and are involved in a two 
sensory mechanism (PEPT1 and calcium-sensing) receptor21. Also, proline-containing di- and 
tripeptides can cause a prophylactic antidiabetic effect in the experimental insulin-dependent 
diabetes mellitus in rats24.  
Recent findings showed that Akt-2 regulated beta cell mass by modulating proliferation, cell 
size and apoptosis33, 34. The GLP1 promotes islet-cells survival via the second messenger 
cAMP. The cAMP as a main regulator in beta cell growth and survival, promotes insulin 
secretion and enhances the activation of the Akt-2 in response to insulin for promoting cell 
survival. The cAMP level in the intracellular space has important effects on ion channels and 
exocytosis of insulin granules.  
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In the present study, peptides A and D prevented endocrine beta cells injury and caused 
survival by reinforcing of the intracellular signaling of Akt-2 and cAMP in mice exposed to 
STZ oxidation and toxicity. There is a direct link between cell metabolism and the signaling 
cascade of beta cells for insulin secretion, cell growth, differentiation and survival of the cell. 
This link is important in understanding beta cells dysfunction with loss of insulin release in 
T2D46. Impaired glucose-induced cAMP formation has been reported in islets from diabetic 
animal models with reduced insulin secretion and cAMP-elevating agents have been found to 
ameliorate beta cells function in diabetes. The key amino acids Leu and Pro and their small 
peptides play a crucial role in the mediation of the insulin secretion by modulating beta cell 
signaling.  
The tripeptide glutathione is the most important non-enzymatic soluble intracellular 
antioxidant and has many metabolic functions in cellular metabolism, including attenuation 
of oxidative stress and inflammation45, 46. The authors have demonstrated that carnosine and 
hannaneh peptides promotes beta cells survival and therefore represents a new and promising 
peptide for therapeutic and prevention strategies aimed at improving cell mass and function. 
In this present study, the hannaneh peptide had multiple functions including anti-DPP-4 and 
insulin secretion stimulator causing normal conditions in beta cells signaling and triggering 
blood glucose homeostasis and a balance in body weight for prevention from diabetes 
induced by MLDS in mice model.  
In conclusion, the Leucine-glycine (Hannaneh) as a dipeptide with natural L-amino acids and 
carnosine may exhibit controlling effects on blood glucose homeostasis by protection of beta 
cell signaling and anti DPP-4 activity, and also body weight loss curbing with hannaneh, 
influenced by the diabetes induction. Based on the new strategies for peptides delivery and 
the ability of the gastrointestinal system to directly absorb the dipeptides, hannaneh and 
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carnosine may grasp some attraction as pharmaceutical agents to attenuate diabetes 
development.  
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Figure legends 
Figure 1. The chemical structures of the studied peptides. A: Ala-His (carnosine), B: Glu-
Cys-Gly (glutathione), C: Leu-Pro-Pro, D: Leu-Gly, E: Pro-Gly-Pro, F: Pro-Pro, G: Pro-
Gly. These chemical structures were designed using Marvin Beans, 16.8.22.0 (Marvin 
Sketch) software for windows in a two-dimensional manner 
Figure 2. The effect of the studied peptides administration on the blood glucose levels in 
diabetes-induced mice at days 10 (L: left) and 12 (R: right) of the experiment. CON: Control 
group (only citrate buffer injection), DI: Exposed to diabetes, DM: DI and 3% dimethyl 
sulfoxide (DMSO) as the solvent for the peptides (without a peptide), A: DM + Ala-His 
(carnosine), B: DM + Glu-Cys-Gly (glutathione), C: DM + Leu-Pro-Pro, D: DM + Leu-Gly, 
E: DM + Pro-Gly-Pro, F: DM + Pro-Pro, G: DM + Pro-Gly. The mean columns of each 
diagram with no common superscript letter differ significantly (P<0.05) (n=10) 
Figure 3. The effect of the administration of the studied peptides on the body weight of 
diabetes-induced mice at the first (35.38±0.27 g in all treatments), 6th and 12th days of the 
experiment. CON: Control group (only citrate buffer injection), DI: Exposed to diabetes, 
DM: DI and 3% dimethyl sulfoxide (DMSO) as the solvent for the peptides (without a 
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peptide), A: DM + Ala-His (carnosine), B: DM + Glu-Cys-Gly (glutathione), C: DM + Leu-
Pro-Pro, D: DM + Leu-Gly, E: DM + Pro-Gly-Pro, F: DM + Pro-Pro, G: DM + Pro-Gly. 0: 
non-significant with the first day of the experiment, +: significant increase (P<0.05), + +: 
very significant increase (P<0.01), - : significant decrease (P<0.05), - - : very significant 
decrease (P<0.01) (n=10) 
Figure 4. The effect of peptide administration on the plasma insulin level in diabetes-induced 
mice on the 6th and 12th experimental days. CON: Control group (only citrate buffer 
injection), DI: Exposed to diabetes, DM: DI and 3% dimethyl sulfoxide (DMSO) as the 
solvent for the peptides (without a peptide), A: DM + Ala-His (carnosine), B: DM + Glu-
Cys-Gly (glutathione), C: DM + Leu-Pro-Pro, D: DM + Leu-Gly, E: DM + Pro-Gly-Pro, F: 
DM + Pro-Pro, G: DM + Pro-Gly. The mean columns of each diagram with no common 
superscript letter differ significantly (P<0.05) (n=10) 
Figure 5. The effect of peptide administration on the intracellular Akt-2 and cAMP levels in 
diabetes-induced mice at the end of the experiment. CON: Control group (only citrate buffer 
injection), DI: Exposed to diabetes, DM: DI and 3% dimethyl sulfoxide (DMSO) as the 
solvent for the peptides (without a peptide), A: DM + Ala-His (carnosine), B: DM + Glu-
Cys-Gly (glutathione), C: DM + Leu-Pro-Pro, D: DM + Leu-Gly, E: DM + Pro-Gly-Pro, F: 
DM + Pro-Pro, G: DM + Pro-Gly. The mean columns of each diagram with no common 
superscript letter differ significantly (P<0.05) (n = 10) 
Figure 6. The effect of administration of the studied peptides. A: Ala-His (carnosine), B: 
Glu-Cys-Gly (glutathione), C: Leu-Pro-Pro, D: Leu-Gly, E: Pro-Gly-Pro, F: Pro-Pro, and G: 
Pro-Gly compared to control (CON), exposed to diabetes (DI), and DI+ 3% DMSO (DM) on 
beta cell function assessed by immunofluorescence staining of the islets on the 12th day of 
the experiment (the insulin content of the beta cells is shown in green and glucagon-
producing alpha cells are red, Original magnification: 1000X) 
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TABLE 1. Comparison of mean plasma glucose level (mg/dl) between treatments at different time points 
(2, 4, 6, 8, 10, and 12 days) 
Treatments   Time  (day)    
Time stages 2 4 6 8 10 12 
CON 94.6±1.7b 107.4±3.1abc 120.3±4.2abc 99.2±4.0a 111.7±4.5a 118.7±4.5a 
DI 111.6±2.1cd 113.9±2.5bc 146.4±4.5cd 159.8±4.9b 174.8±6.8b 279.3±14.5d 
DM 104.4±2.0bcd 122.4±2.4cd 134.3±3.2bcd 133.3±4.3ab 177.3±6.5b 219.1±12.1c 
A 101.1±1.7bc 94.3±2.2ab 98.0±2.8a 126.1±4.0ab 116.4±4.3a 138.8±4.9ab 
B 117.9±2.3d 109.7±3.1abc 108.9±3.5ab 134.2±4.4ab 127.3±5.0ab 199.6±8.1bc 
C 104.4±1.8bcd 113.2±3.3bc 121.0±4.3abc 143.4±4.9b 159.6±5.7ab 190.4±7.2bc 
D 110.3±1.9bcd 138.2±4.1d 150.6±4.6cd 145.0±4.8b 112.0±4.9a 146.0±5.1ab 
E 78.9±1.4a 86.4±2.0a 139.9±4.0bcd 144.8±4.7b 140.9±5.5ab 172.6±8.1abc 
F 118.4±2.0d 109.6±2.4abc 130.0±4.0abcd 127.1±3.9ab 129.3±4.9ab 157.9±5.7ab 
G 109.7±2.1bcd 101.7±2.9abc 121.4±3.1abc 139.3±4.0ab 132.8±4.4ab 186.8±7.9bc 
P-Value  0.00 0.00 0.01 0.05 0.03 0.00 
Means ± SD within each column with no common superscript letter differ significantly. CON: Control 
group (only citrate buffer injection), DI: Exposed to diabetes, DM: DI and 3% dimethyl sulfoxide (DMSO) 
as the solvent of the peptides (without of peptide), A: DM + Ala-His (Carnosine), B: DM + Glu-Cys-Gly 
(Glutathione), C: DM + Leu-Pro-Pro, D: DM + Leu-Gly, E: DM + Pro-Gly-Pro, F: DM + Pro-Pro, G: DM 
+ Pro-Gly, (n =10) 
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TABLE 2. Comparison of mean plasma GLP-1 level and DPP-4 activity between treatments at two 
time points (6 and 12 days)  
Parameter 
 
GLP-1 
(ng/L) 
GLP-1 
(ng/L) 
DPP-4 
(ng/ml) 
DPP-4 
(ng/ml) 
Time stages          6 12 6 12 
CON 332.5±9.1ab 303.4±8.1abcd 1.9±0.0ab 1.9±0.0 
DI 461.9±15.4c 286.0±9.5abcd 2.0±0.1a 1.9±0.1 
DM 339.1±11.6ab 255.3±8.2ab 1.6±0.1abcd 1.8±0.1 
A 277.8±8.9a 340.5±9.4cd 1.5±0.1bcd 1.8±0.0 
B 405.4±12.4bc 346.7±10.0d 1.6±0.1abcd 2.1±0.1 
C 350.8±11.0ab 275.0±8.9abcd 1.6±0.1abcd 1.8±0.1 
D 338.2±9.1ab 249.5±8.6a 1.5±0.0cd 1.8±0.0 
E 330.8±9.3ab 262.9±9.8abc 1.7±0.0abcd 1.9±0.0 
F 331.5±9.7ab 235.3±9.1a 1.4±0.0d 1.8±0.0 
G 387.2±9.6bc 336.6±9.8bcd 1.9±0.0abc 1.7±0.0 
P-Value  0.01 0.02 0.03 0.66 
Means ± SD within each column with no common superscript letter differ significantly. CON: Control 
group (only citrate buffer injection), DI: Exposed to diabetes, DM: DI and 3% dimethyl sulfoxide 
(DMSO) as the solvent of the peptides (without of peptide), A: DM + Ala-His (Carnosine), B: DM + 
Glu-Cys-Gly (Glutathione), C: DM + Leu-Pro-Pro, D: DM + Leu-Gly, E: DM + Pro-Gly-Pro, F: DM + 
Pro-Pro, G: DM + Pro-Gly, (n =10) 
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